101,450 Shares in Gilead Sciences, Inc. $GILD Acquired by Callan Family Office LLC

Posted by Geri Gentry on Aug 22nd, 2026

Gilead Sciences logo Callan Family Office LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the second quarter, Holdings Channel.com reports. The fund bought 101,450 shares of the biopharmaceutical company’s stock, valued at approximately $12,817,000.

Other institutional investors also recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences during the 4th quarter worth $25,000. Vermillion & White Wealth Management Group LLC lifted its position in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares during the last quarter. Quattro Advisors LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth $26,000. Finally, Wealth Preservation Advisors LLC grew its stake in shares of Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Daiwa Securities Group dropped their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a report on Wednesday, May 20th. Finally, Royal Bank Of Canada raised their target price on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Twenty-four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $158.04.

View Our Latest Research Report on Gilead Sciences

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the transaction, the chief financial officer owned 165,646 shares of the company’s stock, valued at $22,918,780.56. The trade was a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. This represents a 33.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 87,000 shares of company stock valued at $11,562,960 over the last quarter. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $146.12 on Friday. The company’s fifty day moving average price is $131.97 and its 200 day moving average price is $136.59. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The firm has a market capitalization of $181.18 billion, a P/E ratio of -54.73 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the prior year, the firm posted $2.01 earnings per share. Gilead Sciences’s revenue for the quarter was up 10.6% on a year-over-year basis. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post -0.51 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is presently -122.85%.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.